Longitudinal antibody responses to peanut following probiotic and peanut oral immunotherapy (PPOIT) in children with peanut allergy.

Show simple item record

dc.contributor.author Hsiao, Kuang-Chih
dc.contributor.author Ponsonby, Anne-Louise
dc.contributor.author Ashley, Sarah
dc.contributor.author Lee, Cassandra Yuen Yan
dc.contributor.author Jindal, Lalita
dc.contributor.author PPOIT Study Team
dc.contributor.author Masters of advanced practice nursing
dc.contributor.author Tang, Mimi LK
dc.coverage.spatial England
dc.date.accessioned 2022-06-22T22:16:32Z
dc.date.available 2022-06-22T22:16:32Z
dc.date.issued 2022-04-11
dc.identifier.citation (2022). Clinical and Experimental Allergy.
dc.identifier.issn 0954-7894
dc.identifier.uri https://hdl.handle.net/2292/60108
dc.description.abstract <h4>Introduction</h4>Probiotic and Peanut Oral Immunotherapy (PPOIT) is effective at inducing sustained unresponsiveness (SU) at end-of-treatment and this effect persists up to four years post-treatment, referred to as persistent SU. We sought to evaluate (i) how PPOIT altered peanut-specific humoral immune indices, and (ii) how such longitudinal indices relate to persistent SU.<h4>Methods</h4>Longitudinal serum/plasma levels of whole peanut- and peanut component- (Ara-h1, -h2, -h3, -h8, -h9) specific-IgE (sIgE) and specific-IgG4 (sIgG4) antibodies were measured by ImmunoCAP and salivary peanut-specific-IgA (sIgA) by ELISA in children (n=62) enrolled in the PPOIT-001 randomised trial from baseline (T0) to 4-years post-treatment (T5). Multivariate regression analyses of log-transformed values were used for point-in-time between group comparisons. Generalised estimating equations (GEE) were used for longitudinal comparisons between groups.<h4>Results</h4>PPOIT was associated with changes in sIgE and sIgG4 over time. sIgE levels were significantly reduced post-treatment [T5, PPOIT v.s. Placebo ratio of geometric mean (GM): Ara-h1 0.07, p=0.008; Ara-h2 0.08, p=0.007; Ara-h3 0.15, p=0.021]. sIgG4 levels were significantly increased by end-of-treatment (T1, PPOIT v.s. Placebo ratio of GM: Ara-h1 3.77, p=0.011; Ara-h2 17.97, p<0.001; Ara-h3 10.42, p<0.001) but levels in PPOIT group decreased once treatment was stopped and returned to levels comparable with Placebo group by T5. Similarly, salivary peanut sIgA increased during treatment, as early as 4 months of treatment (PPOIT v.s. Placebo, ratio of GM: 2.04, p=0.014), then reduced post-treatment.<h4>Conclusion</h4>PPOIT was associated with broad reduction in peanut specific humoral responses which may mediate the clinical effects of SU that persists to 4-years post-treatment.
dc.format.medium Print-Electronic
dc.language eng
dc.publisher Wiley
dc.relation.ispartofseries Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher.
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm
dc.subject PPOIT Study Team
dc.subject Masters of advanced practice nursing
dc.subject Peanut allergy
dc.subject antibody responses
dc.subject desensitisation
dc.subject oral immunotherapy
dc.subject probiotic
dc.subject remission
dc.subject sustained unresponsiveness
dc.subject Complementary and Integrative Health
dc.subject Clinical Trials and Supportive Activities
dc.subject Clinical Research
dc.subject Biotechnology
dc.subject Prevention
dc.subject 6.1 Pharmaceuticals
dc.subject 1107 Immunology
dc.subject 1111 Nutrition and Dietetics
dc.subject 1117 Public Health and Health Services
dc.title Longitudinal antibody responses to peanut following probiotic and peanut oral immunotherapy (PPOIT) in children with peanut allergy.
dc.type Journal Article
dc.identifier.doi 10.1111/cea.14146
dc.date.updated 2022-05-12T04:37:54Z
dc.rights.holder Copyright: The author en
dc.identifier.pmid 35403286 (pubmed)
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/35403286
pubs.publication-status Published
dc.rights.accessrights http://purl.org/eprint/accessRights/RestrictedAccess en
pubs.subtype Journal Article
pubs.elements-id 896732
pubs.org-id Medical and Health Sciences
pubs.org-id School of Medicine
pubs.org-id Paediatrics Child & Youth Hlth
dc.identifier.eissn 1365-2222
pubs.record-created-at-source-date 2022-05-12
pubs.online-publication-date 2022-04-29

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace